Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Kidney Int

Retrieve available abstracts of 95 articles:
HTML format

Single Articles

    July 2021
  1. FANG Y, Chen B, Gong AY, Malhotra D, et al
    The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.
    Kidney Int. 2021 Jul 8. pii: S0085-2538(21)00665.
    PubMed     Abstract available

    May 2021
  2. KE G, Chen X, Liao R, Xu L, et al
    Receptor activator of NF-kappaB mediates podocyte injury in diabetic nephropathy.
    Kidney Int. 2021 May 27. pii: S0085-2538(21)00503.
    PubMed     Abstract available

  3. DOU L, Burtey S
    Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome.
    Kidney Int. 2021;99:1062-1064.
    PubMed     Abstract available

    April 2021
  4. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
    A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
    PubMed     Abstract available

    Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation.
    Kidney Int. 2021;99:814-816.
    PubMed     Abstract available

  6. OSHIMA M, Jardine MJ, Agarwal R, Bakris G, et al
    Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
    Kidney Int. 2021;99:999-1009.
    PubMed     Abstract available

    March 2021
  7. WU L, Liu C, Chang DY, Zhan R, et al
    Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy.
    Kidney Int. 2021 Mar 3. pii: S0085-2538(21)00267.
    PubMed     Abstract available

  8. VAN RAALTE DH, Bjornstad P, Heerspink HJL, Persson F, et al
    Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.
    Kidney Int. 2021;99:768-770.

  9. GREGG LP, Navaneethan SD
    Early eGFR decline after SGLT2i initiation: knowns and unknowns.
    Kidney Int. 2021;99:548-550.
    PubMed     Abstract available

  10. KRAUS BJ, Weir MR, Bakris GL, Mattheus M, et al
    Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
    Kidney Int. 2021;99:750-762.
    PubMed     Abstract available

    February 2021
    Cardiovascular and renal risk reduction in type 2 diabetes---which choice?
    Kidney Int. 2021;99:322-323.

  12. NANGAKU M, Wanner C
    Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Kidney Int. 2021;99:318-322.

  13. MANN JFE, Muskiet MHA
    Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2021;99:314-318.

  14. TUTTLE KR, Cherney DZI
    Therapeutic transformation for diabetic kidney disease.
    Kidney Int. 2021;99:301-303.
    PubMed     Abstract available

  15. HEERSPINK HJL, Kohan DE, de Zeeuw D
    New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
    Kidney Int. 2021;99:346-349.
    PubMed     Abstract available

    January 2021
  16. FLOEGE J, Johnson RJ
    Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
    Kidney Int. 2021;99:14-16.

    December 2020
  17. FENG J, Li B, Wang X, Li H, et al
    Low expression of HIV genes in podocytes accelerates the progression of diabetic kidney disease in mice.
    Kidney Int. 2020 Dec 22. pii: S0085-2538(20)31531.
    PubMed     Abstract available

    November 2020
    The ins-and-outs of podocyte lipid metabolism.
    Kidney Int. 2020;98:1087-1090.
    PubMed     Abstract available

  19. HANNA RM, Rhee CM, Kalantar-Zadeh K
    Metformin in chronic kidney disease: a strong dose of caution.
    Kidney Int. 2020;98:1101-1105.

  20. DE BROE ME, Jouret F
    Does metformin do more benefit or harm in chronic kidney disease patients?
    Kidney Int. 2020;98:1098-1101.

    October 2020
  21. MENON R, Otto EA, Sealfon R, Nair V, et al
    SARS-CoV-2 receptor networks in diabetic and COVID-19 associated kidney disease.
    Kidney Int. 2020 Oct 7. pii: S0085-2538(20)31113.
    PubMed     Abstract available

  22. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Int. 2020;98.

    September 2020
  23. SINGH N, Tandukar S, Zibari G, Naseer MS, et al
    Successful Simultaneous Pancreas and Kidney Transplant in a Patient Post-COVID-19 Infection.
    Kidney Int. 2020 Sep 15. pii: S0085-2538(20)31079.

  24. UEKI K, Sasako T, Okazaki Y, Miyake K, et al
    Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.
    Kidney Int. 2020 Sep 3. pii: S0085-2538(20)30974.
    PubMed     Abstract available

    Schlondorff and Lee revealed crosstalk between glomerular cells and a role of BAMBI in diabetic kidney disease.
    Kidney Int. 2020;98:539-541.
    PubMed     Abstract available

    July 2020
  26. LIU X, Ducasa GM, Mallela SK, Kim JJ, et al
    Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport Syndrome.
    Kidney Int. 2020 Jul 30. pii: S0085-2538(20)30837.
    PubMed     Abstract available

  27. IHARA K, Skupien J, Krolewski B, Md Dom ZI, et al
    A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.
    Kidney Int. 2020 Jul 24. pii: S0085-2538(20)30834.
    PubMed     Abstract available

  28. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment.
    Kidney Int. 2020 Jul 10. pii: S0085-2538(20)30798.
    PubMed     Abstract available

    Founding papers of current nephrology: from acute kidney injury to diabetic kidney disease.
    Kidney Int. 2020;98:6-9.

    May 2020
  30. LI J, Neal B, Perkovic V, de Zeeuw D, et al
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
    Kidney Int. 2020 May 26. pii: S0085-2538(20)30565.
    PubMed     Abstract available

    Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
    Kidney Int. 2020;97:855-857.
    PubMed     Abstract available

  32. Corrigendum to "van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients
    Kidney Int. 2020;97:1061.

    Syndecan-4: major player or innocent bystander of the endothelial glycocalyx?
    Kidney Int. 2020;97:858-860.
    PubMed     Abstract available

  34. RAMNATH RD, Butler MJ, Foster RR, Satchell SC, et al
    The authors reply.
    Kidney Int. 2020;97:1057-1058.

    There is little evidence that the endothelial glycocalyx has a specific role in glomerular permeability of albumin.
    Kidney Int. 2020;97:1057.

    April 2020
  36. LAI H, Chen A, Cai H, Fu J, et al
    Podocyte and endothelial-specific elimination of BAMBI identifies differential transforming growth factor-beta pathways contributing to diabetic glomerulopathy.
    Kidney Int. 2020 Apr 26. pii: S0085-2538(20)30429.
    PubMed     Abstract available

  37. HESP AC, Schaub JA, Prasad PV, Vallon V, et al
    The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
    Kidney Int. 2020 Apr 26. pii: S0085-2538(20)30419.
    PubMed     Abstract available

  38. JIA C, Ke-Hong C, Fei X, Huan-Zi D, et al
    Decoy receptor 2 mediation of the senescent phenotype of tubular cells by interacting with peroxiredoxin 1 presents a novel mechanism of renal fibrosis in diabetic nephropathy.
    Kidney Int. 2020 Apr 24. pii: S0085-2538(20)30405.
    PubMed     Abstract available

  39. Corrigendum to "Townsend RR, Guarnieri P, Argyropoulos C, et al.; on behalf of the TRIDENT Study Investigators. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study." Kidney Int. 2020;97:10-13.
    Kidney Int. 2020;97:809.

  40. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    Kidney Int. 2020;97:631-635.

  41. VAN BOMMEL EJM, van Raalte DH
    The authors reply.
    Kidney Int. 2020;97:806.

  42. SOLER MJ, Porrini E, Fernandez-Fernandez B, Ortiz A, et al
    SGLT2i and postglomerular vasodilation.
    Kidney Int. 2020;97:805-806.

    February 2020
  43. BJORNSTAD P, Nehus E, Jenkins T, Mitsnefes M, et al
    Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes.
    Kidney Int. 2020 Feb 3. pii: S0085-2538(20)30114.
    PubMed     Abstract available

  44. SUGAHARA M, Tanaka T, Nangaku M
    Modulating the immune system to delay the clinical onset of type 1 diabetes.
    Kidney Int. 2020;97:248-250.

  45. SALEHI T, Coates PT
    Class effect: dapagliflozin reduces cardiovascular and kidney events.
    Kidney Int. 2020;97:246-248.

    January 2020
  46. BJORNSTAD P, Nelson RG, Pavkov ME
    Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
    Kidney Int. 2020;97:31-33.
    PubMed     Abstract available

  47. LEON-JIMENEZ D, Moreno-Obregon F, Beltran-Romero LM, Miramontes-Gonzalez JP, et al
    Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
    Kidney Int. 2020;97:213.

  48. TOWNSEND RR, Guarnieri P, Argyropoulos C, Blady S, et al
    Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study.
    Kidney Int. 2020;97:10-13.

  49. MAYER GJ, Wanner C, Weir MR, Inzucchi SE, et al
    The authors reply.
    Kidney Int. 2020;97:213-214.

    December 2019
  50. HASEGAWA S, Tanaka T, Saito T, Fukui K, et al
    The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Kidney Int. 2019 Dec 25. pii: S0085-2538(19)31247.
    PubMed     Abstract available

    Prediabetes after kidney transplantation-a reason to worry?
    Kidney Int. 2019;96:1280-1282.
    PubMed     Abstract available

    November 2019
  52. RAMNATH RD, Butler MJ, Newman G, Desideri S, et al
    Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease.
    Kidney Int. 2019 Nov 2. pii: S0085-2538(19)31110.
    PubMed     Abstract available

    October 2019
  53. LIANG X, Wang P, Chen B, Ge Y, et al
    Glycogen synthase kinase 3beta hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.
    Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30992.
    PubMed     Abstract available

  54. VAN BOMMEL EJM, Muskiet MHA, van Baar MJB, Tonneijck L, et al
    The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30991.
    PubMed     Abstract available

  55. ITO M, Nangaku M
    Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
    Kidney Int. 2019;96:823-825.
    PubMed     Abstract available

  56. MARQUEZ A, Batlle D
    Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?
    Kidney Int. 2019;96:815-817.
    PubMed     Abstract available

  57. NISHI H, Nangaku M
    Podocyte lipotoxicity in diabetic kidney disease.
    Kidney Int. 2019;96:809-812.

    September 2019
  58. VERMA N, Liu M, Ly H, Loria A, et al
    Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries.
    Kidney Int. 2019 Sep 5. pii: S0085-2538(19)30844.
    PubMed     Abstract available

    Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?
    Kidney Int. 2019;96:540-542.
    PubMed     Abstract available

    August 2019
  60. KAMMER M, Heinzel A, Willency JA, Duffin KL, et al
    Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes.
    Kidney Int. 2019 Aug 30. pii: S0085-2538(19)30841.
    PubMed     Abstract available

  61. PORRINI E, Diaz JM, Moreso F, Lauzurrica R, et al
    Prediabetes is a risk factor for cardiovascular disease following renal transplantation.
    Kidney Int. 2019 Aug 14. pii: S0085-2538(19)30810.
    PubMed     Abstract available

  62. VAN BAAR MJB, Scholtes RA, van Raalte DH
    SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
    Kidney Int. 2019;96:283-286.
    PubMed     Abstract available

    July 2019
  63. KANDA E, Nangaku M
    Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
    Kidney Int. 2019;96:8-10.

    June 2019
  64. ZHANG D, Gava AL, Van Krieken R, Mehta N, et al
    The caveolin-1 regulated protein follistatin protects against diabetic kidney disease.
    Kidney Int. 2019 Jun 17. pii: S0085-2538(19)30618.
    PubMed     Abstract available

    May 2019
  65. BALMER LA, Whiting R, Rudnicka C, Gallo LA, et al
    Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease.
    Kidney Int. 2019 May 30. pii: S0085-2538(19)30510.
    PubMed     Abstract available

  66. KODAMA Y, Hyodo F, Yamato M, Yasukawa K, et al
    Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.
    Kidney Int. 2019 May 24. pii: S0085-2538(19)30515.
    PubMed     Abstract available

  67. ROSSING P, Block GA, Chin MP, Goldsberry A, et al
    Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
    Kidney Int. 2019 May 16. pii: S0085-2538(19)30503.
    PubMed     Abstract available

  68. CHO ME, Hansen JL, Peters CB, Cheung AK, et al
    An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.
    Kidney Int. 2019 May 15. pii: S0085-2538(19)30506.
    PubMed     Abstract available

  69. CASSIS P, Locatelli M, Corna D, Villa S, et al
    Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
    Kidney Int. 2019 May 10. pii: S0085-2538(19)30486.
    PubMed     Abstract available

    April 2019
  70. BARBOUR S, Djurdjev O, Gill JS, Dong JJ, et al
    A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis.
    Kidney Int. 2019 Apr 1. pii: S0085-2538(19)30388.
    PubMed     Abstract available

    March 2019
  71. MAYER GJ, Wanner C, Weir MR, Inzucchi SE, et al
    Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
    Kidney Int. 2019 Mar 21. pii: S0085-2538(19)30317.
    PubMed     Abstract available

  72. BALLY L, Gubler P, Thabit H, Hartnell S, et al
    Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis.
    Kidney Int. 2019 Mar 20. pii: S0085-2538(19)30322.
    PubMed     Abstract available

  73. LAVOZ C, Matus YS, Orejudo M, Carpio JD, et al
    Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
    Kidney Int. 2019 Mar 8. pii: S0085-2538(19)30124.
    PubMed     Abstract available

  74. CHEN G, Chen H, Ren S, Xia M, et al
    Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease.
    Kidney Int. 2019 Mar 7. pii: S0085-2538(19)30273.
    PubMed     Abstract available

  75. SUNG CC, Chen L, Limbutara K, Jung HJ, et al
    RNA-Seq and protein mass spectrometry in microdissected kidney tubules reveal signaling processes initiating lithium-induced nephrogenic diabetes insipidus.
    Kidney Int. 2019 Mar 4. pii: S0085-2538(19)30267.
    PubMed     Abstract available

    February 2019
  76. XU H, Kuja-Halkola R, Chen X, Magnusson PKE, et al
    Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding.
    Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30047.
    PubMed     Abstract available

  77. CHEN X, Han Y, Gao P, Yang M, et al
    Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy.
    Kidney Int. 2019 Feb 12. pii: S0085-2538(18)30899.
    PubMed     Abstract available

    TRPC6 in diabetic kidney disease: good guy or bad guy?
    Kidney Int. 2019;95:256-258.
    PubMed     Abstract available

    January 2019
  79. CANI PD
    Targeting gut microbiota with a complex mix of dietary fibers improves metabolic diseases.
    Kidney Int. 2019;95:14-16.

    December 2018
  80. CHAUHAN K, Verghese DA, Rao V, Chan L, et al
    Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.
    Kidney Int. 2018 Dec 20. pii: S0085-2538(18)30772.
    PubMed     Abstract available

  81. HIRAKAWA Y, Nangaku M
    Targeting oxidative stress in diabetic kidney disease: a novel drug in an old pathway.
    Kidney Int. 2018;94:1038-1039.

    November 2018
  82. JIANG G, Luk AOY, Tam CHT, Xie F, et al
    Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.
    Kidney Int. 2018 Nov 2. pii: S0085-2538(18)30629.
    PubMed     Abstract available

    September 2018
  83. MICAKOVIC T, Papagiannarou S, Clark E, Kuzay Y, et al
    The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus.
    Kidney Int. 2018 Sep 3. pii: S0085-2538(18)30442.
    PubMed     Abstract available

    July 2018
  84. TANAKA S, Sugiura Y, Saito H, Sugahara M, et al
    Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
    Kidney Int. 2018 Jul 13. pii: S0085-2538(18)30353.
    PubMed     Abstract available

    June 2018
  85. BOMSZTYK K, Denisenko O, Wang Y
    DNA methylation yields epigenetic clues into the diabetic nephropathy of Pima Indians.
    Kidney Int. 2018;93:1272-1275.
    PubMed     Abstract available

    May 2018
  86. FU J, Wei C, Zhang W, Schlondorff D, et al
    Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice.
    Kidney Int. 2018 May 31. pii: S0085-2538(18)30242.
    PubMed     Abstract available

  87. GROVE KJ, Lareau NM, Voziyan PA, Zeng F, et al
    Imaging mass spectrometry reveals direct albumin fragmentation within the diabetic kidney.
    Kidney Int. 2018 May 17. pii: S0085-2538(18)30202.
    PubMed     Abstract available

    February 2018
  88. HONG Q, Zhang L, Das B, Li Z, et al
    Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.
    Kidney Int. 2018 Feb 22. pii: S0085-2538(18)30033.
    PubMed     Abstract available

  89. KOPP C, Linz P, Maier C, Wabel P, et al
    Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging.
    Kidney Int. 2018 Feb 15. pii: S0085-2538(17)30857.
    PubMed     Abstract available

  90. NOWAK N, Skupien J, Smiles AM, Yamanouchi M, et al
    Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.
    Kidney Int. 2018 Feb 2. pii: S0085-2538(17)30892.
    PubMed     Abstract available

  91. PERCO P, Mayer G
    Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?
    Kidney Int. 2018;93:308-310.
    PubMed     Abstract available

    January 2018

  92. Zhang L, Zhang Q, Liu S, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 2017;92:140-153.
    Kidney Int. 2018;93:271.

    December 2017
  93. XIE Y, Bowe B, Li T, Xian H, et al
    Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus.
    Kidney Int. 2017 Dec 7. pii: S0085-2538(17)30676.
    PubMed     Abstract available

    October 2017
  94. NAIR V, Komorowsky CV, Weil EJ, Yee B, et al
    A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.
    Kidney Int. 2017 Oct 18. pii: S0085-2538(17)30610.
    PubMed     Abstract available

  95. CHUN N, Wyatt CM, He JC
    Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy.
    Kidney Int. 2017;92:780-781.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.